Showing results (61-70 of 162) with videos related to

Sort By:
Pageof 17
Gynecologic Oncology|May 17, 2005
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridizationAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
Gynecologic Oncology|August 16, 2014
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivoCarlton L Schwab, Diana P English, Dana M Roque, et al.
American Journal of Obstetrics and Gynecology|November 4, 2008
Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancerStefania Bellone, Simone Anfossi, Timothy J O'Brien, et al.
American Journal of Obstetrics and Gynecology|September 6, 2011
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibodyJoyce Varughese, Emiliano Cocco, Stefania Bellone, et al.
American Journal of Obstetrics and Gynecology|April 16, 2013
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupiloneDana M Roque, Stefania Bellone, Natalia Buza, et al.
Cancer|January 2, 2009
Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancerStefania Bellone, Simone Anfossi, Timothy J O'Brien, et al.
Gynecologic Oncology|May 7, 2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analysesVictoria M Ettorre, Stefania Bellone, Michelle Greenman, et al.
Cancer|August 24, 2005
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinomaAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
Gynecologic Oncology|July 9, 2024
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinomaBlair McNamara, Michelle Greenman, Stefania Bellone, et al.
Cancer Research Communications|August 27, 2025
Preclinical activity of Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate targeting TROP2, in poorly differentiated endometrial carcinomasNiccolo G Santin, Namrata Sethi, Stefania Bellone, et al.
Pageof 17